We equip physicians with innovative extracorporeal therapies that remove excessive harmful inflammatory mediators directly from the bloodstream, helping restore immune balance and improve patient outcomes
By targeting systemic inflammation, a core driver of critical illness, Efferon is expanding beyond intensive care into the broader spectrum of inflammatory diseases
Dima Romashin founded Efferon on the conviction that breakthrough technology only creates value when it reaches patients at scale.
A serial entrepreneur operating at the intersection of medicine, finance, and business, he previously served as an executive in a large manufacturing enterprise with over $100M in annual revenue.
At Efferon, Dima leads corporate strategy, capital formation, and global expansion.
Originator of Efferon's core technology. Ivan brings 20+ years of expertise in functional polymeric materials and composites and 10+ years in the medical device industry.
He leads R&D, technology development, and scientific collaborations from pre-clinical stage through post-market surveillance.
Prior experience spans academia — including scaffold development for tissue engineering at Moscow State University — and industry, including glass-fiber composites at Bautex. MSc in Organic Chemistry, Moscow State University.
Seasoned biotech and pharma executive with 20+ years spanning corporate strategy, M&A, and global commercial initiatives. Prior leadership roles at Pfizer, Goldman Sachs, Deutsche Bank, and UBS.
Earlier, she founded and led MBMR BioLabs, licensing proprietary technology to a top-10 global life science company.
PhD in Biochemistry and Structural Biology, Cornell University / Memorial Sloan-Kettering Cancer Center; MBA, Columbia Business School.
Experienced medtech executive with 25+ years in international business development focused on critical care and blood purification. Alexandru leads global commercialization and market expansion at Efferon, advancing next-generation hemoadsorption technologies into new markets.
Prior positions include senior leadership roles at CytoSorbents Corporation and Gambro, where he built multi-country operations and executed major go-to-market initiatives. MBA, City University of Seattle.
